Eveline Bruinstroop

Eveline Bruinstroop

Auto-generated profile, based on publicly available information

Eveline Bruinstroop

Department of Endocrinology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
AWAnissa A Widjaja
Anissa A Widjaja
BSBrijesh K. Singh
Brijesh K. Singh
EAEleonora Adami
Eleonora Adami
SVSivakumar Viswanathan
Sivakumar Viswanathan
JDJinrui Dong
Jinrui Dong
SCStuart A Cook
Stuart A Cook
Background & Aims We studied the role of interleukin 11 (IL11) signaling in the pathogenesis of nonalcoholic steatohepatitis (NASH) using hepatic stellate cells (HSCs), hepatocytes, and mouse models of NASH. Methods We stimulated mouse and human fibroblasts, HSCs, or hepatocytes with IL11 and other cytokines and analyzed them by imaging, immunoblot, and functional assays and enzyme-linked immunosorbent assays. Mice were given injections of IL11. Mice with disruption of the interleukin 11 receptor subunit alpha1 gene (Il11ra1–/–) mice and Il11ra1+/+ mice were fed a high-fat methionine- and choline-deficient diet (HFMCD) or a Western diet with liquid fructose (WDF) to induce steatohepatitis; control mice were fed normal chow. db/db mice were fed with methionine- and choline-deficient diet for 12 weeks and C57BL/6 NTac were fed with HFMCD for 10 weeks or WDF for 16 weeks. Some mice were given intraperitoneal injections of anti-IL11 (X203), anti-IL11RA (X209), or a control antibody at different timepoints on the diets. Livers and blood were collected; blood samples were analyzed by biochemistry and liver tissues were analyzed by histology, RNA sequencing, immunoblots, immunohistochemistry, hydroxyproline, and mass cytometry time of flight assays. Results HSCs incubated with cytokines produced IL11, resulting in activation (phosphorylation) of ERK and expression of markers of fibrosis. Livers of mice given injections of IL11 became damaged, with increased markers of fibrosis, hepatocyte cell death and inflammation. Following the HFMCD or WDF, livers from Il11ra1–/– mice had reduced steatosis, fibrosis, expression of markers of inflammation and steatohepatitis, compared to and Il11ra1+/+ mice on the same diets. Depending on the time of administration of anti-IL11 or anti-IL11RA antibodies to wild-type mice on the HFMCD or WDF, or to db/db mice on the methionine and choline-deficient diet, the antibodies prevented, stopped, or reversed development of fibrosis and steatosis. Blood samples from Il11ra1+/+ mice fed the WDF and given injections of anti-IL11 or anti-IL11RA, as well as from Il11ra1–/– mice fed WDF, had lower serum levels of lipids and glucose than mice not injected with antibody or with disruption of Il11ra1. Conclusions Neutralizing antibodies that block IL11 signaling reduce fibrosis, steatosis, hepatocyte death, inflammation and hyperglycemia in mice with diet-induced steatohepatitis. These antibodies also improve the cardiometabolic profile of mice and might be developed for the treatment of NASH.

16 December 2011 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
EBEveline Bruinstroop
Eveline Bruinstroop
GCGeorgina Cano
Georgina Cano
VVVeronique G.J.M. Vanderhorst
Veronique G.J.M. Vanderhorst
JCJudney C. Cavalcante
Judney C. Cavalcante
JWJena Wirth
Jena Wirth
CSClifford B. Saper
Clifford B. Saper

11 November 2010 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Andries KalsbeekAndries Kalsbeek
Andries Kalsbeek
EBE. Bruinstroop
E. Bruinstroop
CYChun-Xia Yi
Chun-Xia Yi
LKL.P. Klieverik
L.P. Klieverik
SFS.E La Fleur
S.E La Fleur
EFE. Fliers
E. Fliers

19 October 2024 in Journal of Hepatology
Verified
Journal Article
Open access
VRVlad Ratziu
Vlad Ratziu
TSThomas S. Scanlan
Thomas S. Scanlan
EBEveline Bruinstroop
Eveline Bruinstroop
The association between suboptimal thyroid function ((sub)clinical hypothyroidism or low-normal thyroid function) and the metabolic syndrome and MASLD (metabolic dysfunction-associated steatotic liver disease) has been clearly established. Furthermore, in MASLD, intracellular thyroid hormone concentrations are low and the activation of the thyroid hormone receptor (THR) is reduced. Administration of thyroid hormone has been shown to reduce liver triglycerides by stimulating fatty acid disposal through lipophagy and beta-oxidation, and to lower LDL-cholesterol. As thyroid hormone exerts its effects in many different organs, including the heart and bone, several drug candidates have been developed as selective thyromimetics for the THR-β nuclear receptor with potent and liver-targeted activity. Importantly, these compounds have reduced affinity for the THR-α nuclear receptor and tissue distribution profiles that differ from endogenous thyroid hormones, thereby reducing unwanted cardiovascular side effects. The most advanced compound, resmetirom, is an oral drug that demonstrated, in a large phase III trial in patients with MASH (metabolic dysfunction-associated steatohepatitis), the ability to reduce liver fat, decrease aminotransferase levels and improve atherogenic dyslipidaemia with a good tolerability profile. This translated into histological improvement that led to accelerated approval of this drug for active fibrotic steatohepatitis, a milestone achievement as a first MASH drug.

13 April 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
EBEveline Bruinstroop
Eveline Bruinstroop
LPLei Pei
Lei Pei
MAMariëtte T. Ackermans
Mariëtte T. Ackermans
EFEwout Foppen
Ewout Foppen
ABAnke J. Borgers
Anke J. Borgers
Andries KalsbeekAndries Kalsbeek
Andries Kalsbeek
Excessive secretion of triglyceride-rich very low-density lipoproteins (VLDL-TG) contributes to diabetic dyslipidemia. Earlier studies have indicated a possible role for the hypothalamus and autonomic nervous system in the regulation of VLDL-TG. In the current study, we investigated whether the autonomic nervous system and hypothalamic neuropeptide Y (NPY) release during fasting regulates hepatic VLDL-TG secretion. We report that, in fasted rats, an intact hypothalamic arcuate nucleus and hepatic sympathetic innervation are necessary to maintain VLDL-TG secretion. Furthermore, the hepatic sympathetic innervation is necessary to mediate the stimulatory effect of intracerebroventricular administration of NPY on VLDL-TG secretion. Since the intracerebroventricular administration of NPY increases VLDL-TG secretion by the liver without affecting lipolysis, its effect on lipid metabolism appears to be selective to the liver. Together, our findings indicate that the increased release of NPY during fasting stimulates the sympathetic nervous system to maintain VLDL-TG secretion at a postprandial level.

1 January 2023 in Thyroid®
Verified
Journal Article
Closed access
AFAline C. Fenneman
Aline C. Fenneman
EBEveline Bruinstroop
Eveline Bruinstroop
MNMax Nieuwdorp
Max Nieuwdorp
ASAnne H. van der Spek
Anne H. van der Spek
ABAnita Boelen
Anita Boelen
Background: The gut is a target organ of thyroid hormone that exerts its action via the nuclear thyroid hormone receptor 1 (TR1) expressed in intestinal epithelial cells. Thyroid hormones are partially metabolized via hepatic sulfation and glucuronidation resulting in the production of conjugated iodothyronines. Gut microbiota play an important role in peripheral thyroid hormone metabolism as they produce and secrete enzymes with deconjugation activity (β-glucuronidase and sulfatase), via which TH can re-enter the enterohepatic circulation. Summary: Intestinal epithelium homeostasis (the finely tuned balance between cell proliferation and differentiation) is controlled by the crosstalk between T3 and TRα1 and the presence of specific TH transporters and TH-activating and inactivating enzymes. Patients and experimental murine models with a dominant-negative mutation in the TR exhibit gross abnormalities in the morphology of the intestinal epithelium and suffer from severe symptoms of a dysfunctional gastrointestinal tract. Over the past decade, gut microbiota has been identified as an essential factor in health and disease, depending on its compositional and functional profile. This has led to a renewed interest in the so-called gut-thyroid axis. Disruption of gut microbial homeostasis (dysbiosis) is associated with autoimmune thyroid disease (AITD), including Hashimoto’s thyroiditis (HT), Graves’ disease (GD), and Graves’ orbitopathy (GO). These studies reviewed here provide new insights into the gut microbiota roles in thyroid disease pathogenesis and may be an initial step toward microbiota-based therapies in AITD. However, it should be noted that cause-effect mechanisms remain to be proven, for which prospective cohort studies, randomized clinical trials, and experimental studies are needed. Conclusion: This review aims to provide a comprehensive insight into the interplay between thyroid hormone metabolism and gut homeostasis.